Heart failure, diabetes mellitus, and chronic kidney disease

Circulation: Heart Failure

Volumn 9, Issue 7, 2016, Pages

  Aguilar, David ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

chronic kidney disease; diabetes mellitus; Editorials; heart failure; hyperglycemia; insulin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LIRAGLUTIDE; PLACEBO; SAXAGLIPTIN;

ANTIDIABETIC ACTIVITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG CONTRAINDICATION; EDITORIAL; HEALTH PROGRAM; HEART FAILURE; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; MEDICARE; OUTCOME ASSESSMENT; PATIENT SAFETY; POPULATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; CHRONIC KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84978971003     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.116.003316     Document Type: Editorial

References (18)

1. Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC, Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 2015 3 136 145. doi: 10.1016/j.jchf.2014.08.004
2. Standl E, Schnell O, McGuire DK, Heart failure considerations of antihyperglycemic medications for type 2 diabetes. Circ Res 2016 118 1830 1843. doi: 10.1161/CIRCRESAHA.116.306924
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012 35 1364 1379. doi: 10.2337/dc12-0413
4. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL, Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-Analysis. Eur Heart J 2014 35 455 469. doi: 10.1093/eurheartj/eht386
5. Löfman I, Szummer K, Hagerman I, Dahlström U, Lund LH, Jernberg T, Prevalence and prognostic impact of kidney disease on heart failure patients. Open Heart 2016 3 e000324. doi: 10.1136/openhrt-2015-000324
6. National Kidney Foundation KDOQI clinical practice guideline for diabetes and CKD: 2012 update Am J Kidney Dis 2012 60 850 886. doi: 10.1053/j.ajkd.2012.07.005
7. Roussel R, Lorraine J, Rodriguez A, Salaun-Martin C, Overview of data concerning the safe use of antihyperglycemic medications in type 2 diabetes mellitus and chronic kidney disease Adv Ther 2015 32 1029 1064. doi: 10.1007/s12325-015-0261-x
8. Patel PA, Liang L, Khazanie P, Hammill BG, Fonarow GC, Yancy CW, Bhatt DL, Curtis LH, Hernandez AF, Antihyperglycemic medication use among Medicare beneficiaries with heart failure, diabetes, and chronic kidney disease. Circ Heart Fail 2016 9 e002638. doi: 10.1161/CIRCHEARTFAILURE.115.002638
9. Food and Drug Administration Guidance for Industry. Diabetes Mellitus-Evaluation Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes 2008. 2011 Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Accessed June 12, 2016
10. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015 373 232 242. doi: 10.1056/NEJMoa1501352
11. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, for the LEADER Steering Committee on behalf of the LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016. doi: 10.1056/NEJMoa1603827
12. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, ELIXA Investigators Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015 373 2247 2257. doi: 10.1056/NEJMoa1509225
13. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013 369 1317 1326. doi: 10.1056/NEJMoa1307684
14. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013 369 1327 1335. doi: 10.1056/NEJMoa1305889
15. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 373 2117 2128. doi: 10.1056/NEJMoa1504720
16. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, EXAMINE Investigators Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015 385 2067 2076. doi: 10.1016/S0140-6736(14)62225-X
17. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL, SAVOR-TIMI 53 Steering Committee and Investigators Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014 130 1579 1588. doi: 10.1161/CIRCULATIONAHA.114.010389
18. Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im K, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM, SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015 38 696 705. doi: 10.2337/dc14-1850